Investigational drug · Phase 3
SV-BR-1-GM
Also called: the Bria-IMT
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
6
Any phase or sponsor naming "SV-BR-1-GM"
First trial start
2018
Mar 16, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SV-BR-1-GM", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
- Metastatic Breast Cancer
- Breast Neoplasm
- Breast Cancer Metastatic
- End Stage Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SV-BR-1-GM" as an intervention, largest first.
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.Pivotal-lookingRecruiting
BriaCell Therapeutics CorporationIndustry
NCT06072612 · 404 participants (planned) · Start Dec 5, 2023 · Primary completion Dec 2027
Drug: SV-BR-1-GM; Cyclophosphamide and 3 more · For: Breast Cancer; Metastatic Breast Cancer; Breast Neoplasm and 2 more
Sites: Phoenix, Arizona; Tucson, Arizona; Anaheim, California · 79 sites in all
BriaCell Therapeutics CorporationIndustry
NCT03328026 · 36 participants · Start Mar 16, 2018 · Primary completion Mar 24, 2026
Drug: SV-BR-1-GM; Low dose cyclophosphamide and 2 more · For: Breast Cancer; Breast Neoplasm; Metastatic Breast Cancer and 1 more
Sites: Newport Beach, California; Santa Rosa, California; Jacksonville, Florida · 14 sites in all
BriaCell Therapeutics CorporationIndustry
NCT03066947 · 24 participants · Start May 5, 2017 · Primary completion Nov 22, 2018
Drug: SV-BR-1-GM; Cyclophosphamide and 1 more · For: Breastcancer; Breast Neoplasm
Sites: Santa Rosa, California; Plantation, Florida; Wichita, Kansas · 5 sites in all
BriaCell Therapeutics CorporationIndustry
NCT06471673 · 18 participants (planned) · Start May 29, 2024 · Primary completion Apr 30, 2025
Drug: BC1 cell line; Bria-OTS regimen and CPI (tislelizumab) and 1 more · For: Breast Cancer; Breast Tumor; Cancer of Breast and 3 more
Sites: Santa Monica, California
Thomas Jefferson UniversityAcademic, hospital or other
NCT04418219 · 0 participants · Start Dec 21, 2020 · Primary completion Jan 1, 2023
Drug: Cyclophosphamide; Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM and 2 more · For: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 and 2 more
Sites: Philadelphia, Pennsylvania
Medical College of WisconsinAcademic, hospital or other
NCT07199413 · 0 participants · Start Jun 15, 2026 · Primary completion Apr 1, 2029
Drug: SV-BR-1-GM Vaccine; Cyclophosphamide and 2 more · For: Brain Metastases; Leptomeningeal Metastasis
Newest research
PubMed records naming it or its code names, newest first.
- Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer.
Wiseman CL, Holmes JP, Calfa C, et al. · Hum Vaccin Immunother 2024
- Regression of Breast Cancer Metastases Following Treatment with Irradiated SV-BR-1-GM, a GM-CSF Overexpressing Breast Cancer Cell Line: Intellectual Property and Immune Markers of Response.
Wiseman CL, Kharazi A, Sunkari VG, et al. · Recent Pat Anticancer Drug Discov 2022
- SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes.
Lacher MD, Bauer G, Fury B, et al. · Front Immunol 2018
- Objective clinical regression of metastatic breast cancer in disparate sites after use of whole-cell vaccine genetically modified to release sargramostim.
Wiseman CL, Kharazi A · Breast J 2006
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.